Fujii H, Iwaki M, Hayashi H, et al. Clinical outcomes in biopsy-proven nonalcoholic fatty liver disease patients: a multicenter registry-based cohort study. Clin Gastroenterol Hepatol. 2023;21:370–9. https://doi.org/10.1016/j.cgh.2022.01.002.

Article  PubMed  Google Scholar 

Kamada Y, Nakamura T, Isobe S, et al. SWOT analysis of noninvasive tests for diagnosing NAFLD with severe fibrosis: an expert review by the JANIT Forum. J Gastroenterol. 2023;58:79–97. https://doi.org/10.1007/s00535-022-01932-1.

Article  PubMed  Google Scholar 

Hayashi H, Kamada Y, Fujii H, et al. Prediction of liver-related events with a combination of liver stiffness measurements and controlled attenuation parameters in japanese patients with biopsy-proven non-alcoholic fatty liver disease. Ultrasound Med Biol. 2023;49:1658–64. https://doi.org/10.1016/j.ultrasmedbio.2023.03.023.

Article  PubMed  Google Scholar 

Miura K, Hayashi H, Kamada Y, et al. Agile 3+ and Agile 4, noninvasive tests for liver fibrosis, are excellent formulae to predict liver-related events in nonalcoholic fatty liver disease. Hepatol Res. 2023;53:978–88. https://doi.org/10.1111/hepr.13938.

Article  PubMed  Google Scholar 

Arai T, Takahashi H, Seko Y, et al. Accuracy of the enhanced liver fibrosis test in patients with type 2 diabetes mellitus and its clinical implications. Clin Gastroenterol Hepatol. 2023. https://doi.org/10.1016/j.cgh.2023.11.022.

Article  PubMed  Google Scholar 

ElSayed NA, Aleppo G, Aroda VR, et al. Comprehensive medical evaluation and assessment of comorbidities: standards of care in diabetes-2023. Diabetes Care. 2023;46:S49-s67. https://doi.org/10.2337/dc23-S004.

Article  PubMed  Google Scholar 

Sterling RK, Patel K, Duarte-Rojo A, et al. AASLD practice guideline on blood-based non-invasive liver disease assessments of hepatic fibrosis and steatosis. Hepatology. 2024. https://doi.org/10.1097/hep.0000000000000845.

Article  PubMed  Google Scholar 

Kuno A, Ikehara Y, Tanaka Y, et al. A serum “sweet-doughnut” protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Sci Rep. 2013;3:1065. https://doi.org/10.1038/srep01065.

Article  PubMed  PubMed Central  Google Scholar 

Iacobelli S, Arno E, D’Orazio A, et al. Detection of antigens recognized by a novel monoclonal antibody in tissue and serum from patients with breast cancer. Cancer Res. 1986;46:3005–10.

PubMed  Google Scholar 

Grassadonia A, Tinari N, Iurisci I, et al. 90K (Mac-2bp) and galectins in tumor progression and metastasis. Glycoconj J. 2004;19:551–6. https://doi.org/10.1023/B:GLYC.0000014085.00706.d4.

Article  Google Scholar 

Przybylo M, Martuszewska D, Pochec E, et al. Identification of proteins bearing beta1-6 branched N-glycans in human melanoma cell lines from different progression stages by tandem mass spectrometry analysis. Biochim Biophys Acta. 2007;1770:1427–35. https://doi.org/10.1016/j.bbagen.2007.05.006.

Article  PubMed  Google Scholar 

Koths K, Taylor E, Halenbeck R, et al. Cloning and characterization of a human Mac-2-binding protein, a new member of the superfamily defined by the macrophage scavenger receptor cysteine-rich domain. J Biol Chem. 1993;268:14245–9.

Article  PubMed  Google Scholar 

Tinari N, Kuwabara I, Huflejt ME, et al. Glycoprotein 90K/MAC-2BP interacts with galectin-1 and mediates galectin-1-induced cell aggregation. Int J Cancer J Int Cancer. 2001;91:167–72.

Article  Google Scholar 

Resnick D, Pearson A, Krieger M. The SRCR superfamily: a family reminiscent of the Ig superfamily. Trends Biochem Sci. 1994;19:5–8.

Article  PubMed  Google Scholar 

Trahey M, Weissman IL. Cyclophilin C-associated protein: a normal secreted glycoprotein that down-modulates endotoxin and proinflammatory responses in vivo. Proc Natl Acad Sci USA. 1999;96:3006–11.

Article  PubMed  PubMed Central  Google Scholar 

Ochieng J, Leite-Browning ML, Warfield P. Regulation of cellular adhesion to extracellular matrix proteins by galectin-3. Biochem Biophys Res Commun. 1998;246:788–91. https://doi.org/10.1006/bbrc.1998.8708.

Article  PubMed  Google Scholar 

Artini M, Natoli C, Tinari N, et al. Elevated serum levels of 90K/MAC-2 BP predict unresponsiveness to alpha-interferon therapy in chronic HCV hepatitis patients. J Hepatol. 1996;25:212–7. https://doi.org/10.1016/S0168-8278(96)80076-6.

Article  PubMed  Google Scholar 

Cheung KJ, Tilleman K, Deforce D, et al. The HCV serum proteome: a search for fibrosis protein markers. J Viral Hepat. 2009;16:418–29. https://doi.org/10.1111/j.1365-2893.2009.01083.x.

Article  PubMed  Google Scholar 

Kamada Y, Fujii H, Fujii H, et al. Serum Mac-2 binding protein levels as a novel diagnostic biomarker for prediction of disease severity and nonalcoholic steatohepatitis. Proteom Clin Appl. 2013;7:648–56. https://doi.org/10.1002/prca.201200137.

Article  Google Scholar 

Kamada Y, Ono M, Hyogo H, et al. A novel noninvasive diagnostic method for nonalcoholic steatohepatitis using two glycobiomarkers. Hepatology. 2015;62:1433–43. https://doi.org/10.1002/hep.28002.

Article  PubMed  Google Scholar 

Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966–86. https://doi.org/10.1097/hep.0000000000000520.

Article  PubMed  Google Scholar 

Hagström H, Vessby J, Ekstedt M, et al. 99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical. J Hepatol. 2024;80:e76–7. https://doi.org/10.1016/j.jhep.2023.08.026.

Article  PubMed  Google Scholar 

Younossi ZM, Paik JM, Stepanova M, et al. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease. J Hepatol. 2024;80:694–701. https://doi.org/10.1016/j.jhep.2024.01.014.

Article  PubMed  Google Scholar 

Kamada Y, Fujii H, Suzuki Y, et al. Clinical characteristics of steatotic liver disease categories in a large cohort of Japanese health checkup participants. Gastro Hep Adv. 2024;3(8):1148–56.

Article  PubMed  PubMed Central  Google Scholar 

Haji-Ghassemi O, Gilbert M, Spence J, et al. Molecular basis for recognition of the cancer glycobiomarker, LacdiNAc (GalNAc[beta1–>4]GlcNAc), by Wisteria floribunda Agglutinin. J Biol Chem. 2016;291:24085–95. https://doi.org/10.1074/jbc.M116.750463.

Article  PubMed  PubMed Central  Google Scholar 

Uojima H, Nakabayashi K, Yamasaki K, et al. New chemiluminescent enzyme immunoassay for quantitative measurement of Mac-2 binding protein glycosylation isomer in chronic liver disease. J Gastroenterol. 2023;58:1252–60. https://doi.org/10.1007/s00535-023-02043-1.

Article  PubMed  Google Scholar 

Tamaki N, Kurosaki M, Takahashi Y, et al. Wisteria floribunda agglutinin-positive mac-2 binding protein as a screening tool for significant liver fibrosis in health checkup. Int J Mol Sci. 2020. https://doi.org/10.3390/ijms22010040.

Article  PubMed  PubMed Central  Google Scholar 

Sumida Y, Yoneda M, Seko Y, et al. Surveillance of hepatocellular carcinoma in nonalcoholic fatty liver disease. Diagnostics (Basel). 2020. https://doi.org/10.3390/diagnostics10080579.

Article  PubMed  PubMed Central  Google Scholar 

Pham TTT, Ho DT, Nguyen T. Usefulness of Mac-2 binding protein glycosylation isomer in non-invasive probing liver disease in the Vietnamese population. World J Hepatol. 2020;12:220–9. https://doi.org/10.4254/wjh.v12.i5.220.

Article  PubMed  PubMed Central  Google Scholar 

Narimatsu H. Development of M2BPGi: a novel fibrosis serum glyco-biomarker for chronic hepatitis/cirrhosis diagnostics. Expert Rev Proteom. 2015;12:683–93. https://doi.org/10.1586/14789450.2015.1084874.

Article  Google Scholar 

Miyoshi E, Kamada Y, Suzuki T. Functional glycomics: application to medical science and hepatology. Hepatol Res. 2020;50:153–64. https://doi.org/10.1111/hepr.13459.

Article  PubMed  Google Scholar 

Bekki Y, Yoshizumi T, Shimoda S, et al. Hepatic stellate cells secreting WFA(+)-M2BP: Its role in biological interactions with Kupffer cells. J Gastroenterol Hepatol. 2017;32:1387–93. https://doi.org/10.1111/jgh.13708.

Article  PubMed